Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novo Nordisk's liquid growth hormone approved in the E.U.

Sep. 17, 1999

Alliance announces agreement with FDA for phase III trials of blood substitute product

Sep. 17, 1999

AstraZeneca and Knoll establish marketing agreement for Reductil

Sep. 16, 1999

Novavax commences phase III trial of Estrasorb in menopausal women

Sep. 15, 1999

Finasteride and flutamide compared as therapy for idiopathic hirsutism

Sep. 15, 1999

Alteon and Taisho enter option agreement for AGE crosslink breaker

Sep. 14, 1999

Newly patented naphthyridines antagonize IL-4 and enhance G-CSF production

Sep. 14, 1999

NovoRapid approved in E.U. for treatment of diabetes

Sep. 10, 1999

Health Canada approves new type II diabetes treatment from Novo Nordisk

Sep. 10, 1999

Pyridorin enters clinical trials for treatment of diabetic kidney disease

Sep. 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...